These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 28328042)

  • 21. Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse.
    Lobodasch K; Fröhlich F; Rengsberger M; Schubert R; Dengler R; Pachmann U; Pachmann K
    Breast; 2007 Apr; 16(2):211-8. PubMed ID: 17291754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
    Caudle AS; Gonzalez-Angulo AM; Hunt KK; Liu P; Pusztai L; Symmans WF; Kuerer HM; Mittendorf EA; Hortobagyi GN; Meric-Bernstam F
    J Clin Oncol; 2010 Apr; 28(11):1821-8. PubMed ID: 20231683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-spatial-resolution bilateral contrast-enhanced breast MRI at 3 T: preoperative staging of patients diagnosed with invasive lobular cancer.
    Schmitz AC; Meeuwis C; Veldhuis WB; van Hillegersberg R; Schipper ME; van den Bosch MA
    Breast J; 2008; 14(2):206-8. PubMed ID: 18315693
    [No Abstract]   [Full Text] [Related]  

  • 25. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.
    Helvie MA; Joynt LK; Cody RL; Pierce LJ; Adler DD; Merajver SD
    Radiology; 1996 Feb; 198(2):327-32. PubMed ID: 8596826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of re-excision among women undergoing breast-conserving surgery for cancer.
    Waljee JF; Hu ES; Newman LA; Alderman AK
    Ann Surg Oncol; 2008 May; 15(5):1297-303. PubMed ID: 18259820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
    Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
    J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy.
    Hofmann G; Balic M; Dandachi N; Resel M; Schippinger W; Regitnig P; Samonigg H; Bauernhofer T
    Clin Biochem; 2013 Oct; 46(15):1585-9. PubMed ID: 23792261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
    Tsunoda-Shimizu H; Hayashi N; Hamaoka T; Kawasaki T; Tsugawa K; Yagata H; Kikuchi M; Suzuki K; Nakamura S
    Breast Cancer; 2008; 15(2):133-40. PubMed ID: 18288570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
    Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
    Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?
    Guiu S; Wolfer A; Jacot W; Fumoleau P; Romieu G; Bonnetain F; Fiche M
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):235-57. PubMed ID: 25129506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic tumor markers, lymph node status, and decision about adjuvant chemotherapy for breast cancer.
    Velanovich V
    Am Surg; 1997 Apr; 63(4):330-3. PubMed ID: 9124752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
    Mahtani RL; Vogel CL
    J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
    [No Abstract]   [Full Text] [Related]  

  • 37. Duodenal obstruction as the presenting manifestation of recurrent breast cancer.
    Shrestha S; Shah BK; Tandukar S
    J Cancer Res Ther; 2014; 10(3):761-2. PubMed ID: 25313779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infiltrating lobular carcinoma of the breast: systemic treatment.
    Farese SA; Aebi S
    Breast Dis; 2008-2009; 30():45-52. PubMed ID: 19850995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.
    Dixon JM; Renshaw L; Dixon J; Thomas J
    Breast Cancer Res Treat; 2011 Dec; 130(3):871-7. PubMed ID: 21870129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Infiltrating lobular breast cancer: histological and immunohistochemical characteristics].
    Vishnevskaia IaV; Ermilova VD; Savelov NA; Nechushkin MI; Trigolosov AV; Petrovskiĭ AV; Chemeris GIu; Zakharova TI
    Arkh Patol; 2005; 67(4):17-21. PubMed ID: 16209292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.